

*Treatment Strategies for Dyslipidemia*

This second part of a 3-part supplement series to *The American Journal of Managed Care* addresses various clinical and economic aspects of statin therapy in treating dyslipidemia.

---

*Faculty*

**Lori Funk, PharmD**

Clinical Pharmacist  
Cape Fear Valley Health System  
Highsmith-Rainey Memorial Hospital  
Fayetteville, North Carolina

**Robert M. Guthrie, MD**

Professor  
College of Medicine and Public Health  
Ohio State University  
Columbus, Ohio

**Terrance Killilea, PharmD**

Vice President of Pharmacy  
Regence Blue Shield of Idaho  
Boise, Idaho

**James M. McKenney, PharmD**

Professor Emeritus  
Virginia Commonwealth University  
President and Chief Executive Officer  
National Clinical Research, Inc  
Richmond, Virginia

---

## *Disclosure Statement*

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **Robert M. Guthrie, MD**

*Grant/Research support from:*

Abbott Laboratories  
Boehringer Ingelheim  
Bristol-Myers Squibb  
GlaxoSmithKline

*Consultant for:*

AstraZeneca

*Speaker's bureau/Honorarium:*

AstraZeneca

■ **James M. McKenney, PharmD**

*Speaker's honoraria from:*

AstraZeneca  
KOS  
Merck/Schering-Plough  
Pfizer  
Reliant

*Research grant support from:*

AstraZeneca  
GlaxoSmithKline  
KOS  
Merck  
Pfizer  
Roche (research grant to National  
Clinical Research, Inc)  
Schering-Plough  
Takeda

*Consulting services provided for:*

AstraZeneca  
KOS  
Microbia  
Pfizer  
Sankyo

The following participants have declared no financial affiliations with corporate organizations:

■ **Lori Funk, PharmD**

■ **Terrance Killilea, PharmD**

We would like to thank Wayne Kuznar for editorial assistance in the development of two of these articles (as noted in footnotes).

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

---

## *Treatment Strategies for Dyslipidemia*

### **Funding**

This publication was made possible by a grant from **AstraZeneca**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.